The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.

Autor:	Ormond L; École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Liu P; Department of Medicine, University of Massachusetts Medical School., Matuszewski S; École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Renzette N; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School., Bank C; École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.; Instituto Gulbenkian de Ciência, Oeiras, Portugal., Zeldovich K; Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School., Bolon DN; Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School., Kowalik TF; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School., Finberg RW; Department of Medicine, University of Massachusetts Medical School., Jensen JD; École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.; School of Life Sciences, Center for Evolution & Medicine, Arizona State University., Wang JP; Department of Medicine, University of Massachusetts Medical School.
Jazyk:	angličtina
Zdroj:	Genome biology and evolution [Genome Biol Evol] 2017 Jul 01; Vol. 9 (7), pp. 1913-1924.
DOI:	10.1093/gbe/evx138
Abstrakt:	Influenza virus inflicts a heavy death toll annually and resistance to existing antiviral drugs has generated interest in the development of agents with novel mechanisms of action. Favipiravir is an antiviral drug that acts by increasing the genome-wide mutation rate of influenza A virus (IAV). Potential synergistic benefits of combining oseltamivir and favipiravir have been demonstrated in animal models of influenza, but the population-level effects of combining the drugs are unknown. In order to elucidate the underlying evolutionary processes at play, we performed genome-wide sequencing of IAV experimental populations subjected to serial passaging in vitro under a combined protocol of oseltamivir and favipiravir. We describe the interplay between mutation, selection, and genetic drift that ultimately culminates in population extinction. In particular, selective sweeps around oseltamivir resistance mutations reduce genome-wide variation while deleterious mutations hitchhike to fixation given the increased mutational load generated by favipiravir. This latter effect reduces viral fitness and accelerates extinction compared with IAV populations treated with favipiravir alone, but risks spreading both established and newly emerging mutations, including possible drug resistance mutations, if transmission occurs before the viral populations are eradicated. (© The Author 2017. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu